CRT0066101 is primarily used as a selective inhibitor of the MDM2-p53 protein-protein interaction, making it a valuable tool in cancer research. It functions by disrupting the binding of the MDM2 protein to the tumor suppressor p53, thereby stabilizing and activating p53 in cancer cells. This activation leads to cell cycle arrest and apoptosis, particularly in tumor cells that overexpress MDM2. It is widely applied in preclinical studies to evaluate the therapeutic potential of targeting the MDM2-p53 pathway in various cancers, including sarcomas and certain types of leukemia. Its use helps researchers understand mechanisms of p53 regulation and supports the development of novel anti-cancer agents.